Research Library › Documentation and sourcing
To compare peptide batches, start with comparable records rather than choosing the highest purity percentage. A useful comparison connects each vial to its documentation, distinguishes the measured attributes, and identifies differences that matter for a defined research application.
What should be collected for each batch?
Build a review record before comparing numbers. Keep each certificate connected to the corresponding product, lot identifier, sample description, report date, and document version. Record which information is available and which questions remain unresolved.
This is a documentation-review framework, not a claim that every supplier provides every item. Use it to organize evidence and request missing details.
A practical batch comparison worksheet
| Record | Question to ask for both batches |
|---|---|
| Material identity | Are the intended sequence, terminal form, or compound specification the same? |
| Lot connection | Does the vial identifier match the certificate? |
| Reported attribute | Is the result identity, purity, quantitative content, or another measurement? |
| Method and units | Are the methods, reporting basis, and units comparable? |
| Sample and dates | What sample was tested, when, and under which report version? |
| Application evidence | Which additional attributes does the research protocol require? |
Why is a purity percentage insufficient?
Chromatographic purity and quantitative content answer different questions. A nominal vial quantity is another separate statement. Compare like attributes before treating two results as equivalent or ranking one batch above another.
For example, “higher purity” is not a complete sourcing decision if one report lacks a clear sample connection or if the methods do not support a direct numerical comparison. Review purity versus identity before combining these attributes into a single quality judgment.
How do method details affect interpretation?
ICH Q2(R2) discusses analytical validation attributes such as specificity/selectivity, accuracy, precision, and reportable range [1]. These concepts help explain why a number should be evaluated together with the procedure that produced it.
The guideline concerns pharmaceutical analytical procedures. It is used here as methodological background, not as a claim that Not Labs research materials are approved medicines or that a particular report is ICH-validated.
For a practical review, ask whether the documents identify the method and what information supports the intended comparison. If that context is unavailable, record the comparison as unresolved instead of filling the gap with assumptions.
What if a study changes batches?
Keep the batch identifier in the experimental record. Document the point at which the material changed and any concurrent changes in handling, matrix, measurement method, or experimental model. Where a protocol requires it, plan a suitable reference comparison before pooling observations.
A new lot is a reason to review documentation, not automatic evidence that it behaves differently. Likewise, matching product names alone are insufficient to establish experimental equivalence.
Which questions should be resolved before selection?
- Can the intended material and lot be identified clearly?
- Can the reported results be connected to that lot?
- Are the compared measurements actually comparable?
- Does the protocol require additional evidence beyond the certificate?
- Are unresolved questions documented and addressed before interpretation?
Review Testing & Verification and How to Read a Peptide COA alongside the current research-compound listings. For missing or ambiguous report information, use the COA red-flags checklist.
Methodological reference
- International Council for Harmonisation (2023). Q2(R2): Validation of Analytical Procedures. Methodological background; this article’s worksheet is an original documentation-review aid.